VolitionRx Limited

AI Score

0

Unlock

0.66
0.04 (6.28%)
At close: Jan 14, 2025, 3:59 PM
0.66
0.02%
After-hours Jan 14, 2025, 08:00 PM EST
undefined%
Bid 0.62
Market Cap 63.33M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.36
PE Ratio (ttm) -1.83
Forward PE n/a
Analyst Buy
Ask 0.68
Volume 49,686
Avg. Volume (20D) 275,521
Open 0.60
Previous Close 0.62
Day's Range 0.60 - 0.66
52-Week Range 0.43 - 1.23
Beta undefined

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company ope...

Sector Healthcare
IPO Date Mar 2, 2012
Employees 101
Stock Exchange AMEX
Ticker Symbol VNRX

Analyst Forecast

According to 4 analyst ratings, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 657.69% from the latest price.

Buy 50.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
5 months ago · Source
-7.19%
VolitionRx shares are trading lower after the comp... Unlock content with Pro Subscription
8 months ago · Source
-14.53%
VolitionRx shares are trading lower after the company reported worse-than-expected Q1 sales results.